Eculizumab biosimilar - Samsung Bioepis
Alternative Names: AMT-904; EPYSQLI; SB-12 - Samsung BioepisLatest Information Update: 23 Apr 2025
At a glance
- Originator Samsung Bioepis
- Developer Samsung Bioepis; Teva Pharmaceutical Industries
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atypical Haemolytic Uraemic Syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria